Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market. It offers GA-map Dysbiosis Test Lx, a molecular assay for profiling the gut microbiota to identify and characterize dysbiosis for treating patients with Irritable Bowel Syndrome, Inflammatory Bowel Disease, diabetes type 2, gut disorder, lifestyle diseases, and leaky-gut syndrome; GA-map COVID-19 Fecal Test Kit, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples; GA-map Dysbiosis Test reagent kit, a CE-IVD documented test, which is a software that performs QC on the run file, calculates the dysbiosis index score and abundance table, and converts sample result into reports; and GA-map Covid fecal test reagent kit, a CE-IVD documented test to detect SARS-CoV-2 in fecal samples. The company was founded in 2008 and is headquartered in Oslo, Norway.